Novartis Entresto® granted expanded indication in chronic heart failure by FDA

  • Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3 
  • Expanded indication enables potential treatment of more adults with left ventricular ejection fraction (LVEF) below normal, the group where benefits are most clearly evident1 
  • Of the more than 6 million Americans …
/by

Novartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector pen

  • Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84% vs 16%)1 
  • Sensoready autoinjector pen ranked highest for “easy to perform self-injection with the pen,” “patient able to use independently” and “ease of preparation and set-up” by both patients and nurses1 
  • Kesimpta is a targeted B-cell therapy that delivers superior efficacy and post hoc analysis showed that …
/by